Shek is a physics graduate from Oxford and has an MBA from the London Business School. He has previously worked with investment bankers Morgan Stanley International, Lazard Brothers, JP Morgan, Monitor Group and the Anglo Chinese Group.
Commenting on the appointment, Fintan Walton, PharmaVentures’ chief executive, said: ‘Our Transactions division is currently working with a number of key companies in the life sciences sector, providing a comprehensive M&A and asset divestment service and has recently celebrated successes for a number of clients including UCB, Sanofi, Helsinn and Dow Chemical. Our client portfolio will benefit from this key appointment to the team.’
PharmaVentures appoints senior director in Transactions
Ping Shek will work on key M&A accounts in healthcare
You may also like
Media
ACG wins Red Dot Design Award for breakthrough Personalised Medicine Concept
ACG’s Personalised Medicine Concept (PMC) has earned the Red Dot Award for high design quality, recognising its pioneering approach to capsule-based personalised health solutions developed through the collaborative OneACG ecosystem